ER+/ HER2 -ve Breast Cancer Pipeline Assessment, Key Companies, And Emerging Drugs

April 22 11:56 2021
ER+/ HER2 -ve Breast Cancer Pipeline Assessment, Key Companies, And Emerging Drugs

Delveinsight Business Research LLP

“ER+/ HER2 -ve Breast Cancer Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the ER+/ HER2 -ve Breast Cancer Market.

The ER+/ HER2 -ve Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the ER+/ HER2 -ve Breast Cancer pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ER+/ HER2 -ve Breast Cancer collaborations, mergers, acquisition, funding, designations, and other product-related details.

Get FREE sample copy at:

The available therapeutics treatment options in ER-positive/HER2-negative Breast Cancer landscape aim to reduce the survival rate of the patient population. Conventionally, endocrine therapies are recommended as first-line treatment management options for ER-Positive breast cancer. And, if ET does not respond well then chemotherapy is suggested by the oncologist.

ER+/ HER2 -ve Breast Cancer Companies:
Jiangsu HengRui Medicine
Odonate Therapeutics
Merck Sharp and Dohme
AstraZeneca Pharmaceuticals
Eli Lilly
Pharmacia and Upjohn Company
Radius Pharmaceuticals
Syndax Pharmaceuticals
Merrimack Pharmaceuticals
Takeda Pharmaceuticals
Eagle Pharmaceuticals
And many others.

ER+/ HER2 -ve Breast Cancer Therapies covered in the report include:
Radium-223 dichloride
Sacituzumab govitecan
Elacestrant (RAD1901)
And many others.

ER+/ HER2 -ve Breast Cancer Pipeline Analysis

ER+/ HER2 -ve Breast Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of ER+/ HER2 -ve Breast Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the ER+/ HER2 -ve Breast Cancer Treatment.

  • ER+/ HER2 -ve Breast Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • ER+/ HER2 -ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ER+/ HER2 -ve Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Scope of the report

  • The ER+/ HER2 -ve Breast Cancer Pipeline Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for ER+/ HER2 -ve Breast Cancer across the complete product development cycle, including all clinical and non-clinical stages.

  • It comprises detailed profiles of ER+/ HER2 -ve Breast Cancer therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

  • Detailed research and development progress and clinical trial of ER+/ HER2 -ve Breast Cancer, results wherever available, are also included in the pipeline study.

  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across ER+/ HER2 -ve Breast Cancer.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for ER+/ HER2 -ve Breast Cancer.    

  • In the coming years, the ER+/ HER2 -ve Breast Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence ER+/ HER2 -ve Breast Cancer Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the ER+/ HER2 -ve Breast Cancer treatment market. Several potential therapies for ER+/ HER2 -ve Breast Cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the ER+/ HER2 -ve Breast Cancer market size in the coming years.  

  • Our in-depth analysis of the ER+/ HER2 -ve Breast Cancer pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of Content

1. Report Introduction

2. ER+/ HER2 -ve Breast Cancer 

3. ER+/ HER2 -ve Breast Cancer Current Treatment Patterns

4. ER+/ HER2 -ve Breast Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. ER+/ HER2 -ve Breast Cancer Late Stage Products (Phase-III)

7. ER+/ HER2 -ve Breast Cancer Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. ER+/ HER2 -ve Breast Cancer Discontinued Products

13. ER+/ HER2 -ve Breast Cancer Product Profiles

14. ER+/ HER2 -ve Breast Cancer Key Companies

15. ER+/ HER2 -ve Breast Cancer Key Products

16. Dormant and Discontinued Products

17. ER+/ HER2 -ve Breast Cancer Unmet Needs

18. ER+/ HER2 -ve Breast Cancer Future Perspectives

19. ER+/ HER2 -ve Breast Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Latest Reports By DelveInsight
ER+/ HER2 -ve Breast Cancer Market
DelveInsight’s ER+/ HER2 -ve Breast Cancer Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and an in-depth understanding of ER+/ HER2 -ve Breast Cancer market trends for the 7MM.

Latest Healthcare Blog – Alpha-1 Antitrypsin Deficiency Treatment Market

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/ on line 7